Stockscreener 앱 받기
2.64
0.76%
0.02
시간 외 거래:
2.64
전일 마감가:
$2.62
열려 있는:
$2.64
하루 거래량:
555.96K
Relative Volume:
0.75
시가총액:
$188.88M
수익:
-
순이익/손실:
$-104.08M
주가수익비율:
-1.8765
EPS:
-1.4069
순현금흐름:
$-89.91M
1주 성능:
+7.32%
1개월 성능:
+0.00%
6개월 성능:
+49.15%
1년 성능:
+45.86%
1일 변동 폭
$2.585
$2.765
1주일 범위
$2.41
$2.99
52주 변동 폭
$1.63
$3.65
엔카르타 Stock (NKTX) Company Profile
명칭
Nkarta Inc
전화
(925) 407-1049
주소
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.64 | 196.03M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
엔카르타 Stock (NKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-08-14 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-07-28 | 개시 | Needham | Buy |
| 2022-07-18 | 개시 | SVB Leerink | Outperform |
| 2022-03-11 | 개시 | Raymond James | Outperform |
| 2022-03-08 | 개시 | H.C. Wainwright | Buy |
| 2022-01-06 | 개시 | William Blair | Outperform |
| 2021-11-18 | 개시 | SMBC Nikko | Outperform |
| 2021-07-16 | 개시 | Oppenheimer | Outperform |
| 2020-08-04 | 개시 | Cowen | Outperform |
| 2020-08-04 | 개시 | Evercore ISI | Outperform |
| 2020-08-04 | 개시 | Mizuho | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
엔카르타 주식(NKTX)의 최신 뉴스
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss and Promising Pipeline Updates Spark 12% Rally - newsline.com
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay - TipRanks
Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay - Stock Titan
Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital - Stock Titan
Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027 - Stock Titan
Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant - Stock Titan
Nkarta (NKTX) director receives stock options on 37,000 common shares - Stock Titan
Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds - Stock Titan
Nkarta director granted options on 37,000 shares | NKTX Insider Trading - Stock Titan
Nkarta (NKTX) director awarded stock options for 37,000 shares at $2.46 - Stock Titan
Nkarta (NKTX) director Angela Thedinga awarded 37,000 stock options - Stock Titan
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - newsline.com
Nkarta Inc. (NKTX) Edges Lower: Assessing Support and Resistance in a Volatile Biotech MarketDefined Outcome ETF - newsline.com
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta Inc. (NKTX) Edges Higher on Above-Average Volume, Nears Key ResistanceDealer Positioning - newsline.com
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressTech Earnings Analysis - The Legal Advocate
NKTX Q1 2026 Earnings: Narrower-than-expected loss lifts sharesEarnings Quality Analysis - newsline.com
Nkarta Inc. (NKTX) Rallies 3.45% as Buyers Defend Key Support LevelSign of Strength - thelegaladvocate.com
Nkarta’s NK Cell Therapy Push Moves Into Outpatient Care - Finimize
Nkarta Inc. (NKTX) Advances 4.25% as Biotech Sector Momentum BuildsMESA MA - thelegaladvocate.com
Nkarta Inc. (NKTX) Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances Pipeline - The Legal Advocate
Nkarta Inc. (NKTX) Holds Steady at $3.03 as Market Awaits CatalystATR Stop - Newser
Nkarta (NKTX) Posts Record Q1 2026 — EPS $-0.37 Blows Past EstimatesRising Community Picks - newser.com
NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing - Stock Titan
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m - simplywall.st
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation - Yahoo Finance
Nkarta Price Target Maintained With a $11.00/Share by Needham - Moomoo
Nkarta, Inc. Stock 12‑Month Price Target Raised to $11.8, Implies 260% Upside - TradingView
Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances - ChartMill
Nkarta (NASDAQ: NKTX) Q1 2026 loss narrows as cash reaches $266.7M - Stock Titan
Nkarta Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - Weekly Voice
Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029 - Stock Titan
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
FDA deal lets Nkarta test autoimmune cell therapy in community clinics - Stock Titan
TradingKey - TradingKey
How Nkarta (NKTX) performance compares to expectations (Momentum Fading) 2026-05-08Social Buzz - newser.com
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat
NKTX Q1'26 Earnings: revenue estimate is 0 USD - TradingView
NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1%Here's Why - MarketBeat
[ARS] Nkarta, Inc. SEC Filing - Stock Titan
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting - Stock Titan
NKTX (Nkarta Inc.) reports wider than expected Q4 2025 loss, shares jump nearly 16 percent on upbeat investor sentiment.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
엔카르타 (NKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엔카르타 주식 (NKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mahmood Nadir | President |
Jan 15 '26 |
Sale |
2.07 |
5,649 |
11,693 |
167,727 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '25 |
Sale |
1.79 |
1,790 |
3,204 |
320,069 |
2.60%
0.94%
자본화:
|
볼륨(24시간):